Jardiance

Jardiance (generic name: empagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.

Empagliflozin acts as a blocker of the SGLT2 protein in the kidney tubules, whose main function is the amount of glucose and sodium reabsorbed in the blood. This ensures that glucose and salt are excreted through consumption and do not return to the blood.

Jardiance reduces the effect on glucose as well as the internal pressure in the working parts of the heart and the storage units of the kidney.

Benefits include:

Improved glycemic control for adults with type 2 diabetes Reduced risk of permanent kidney damage from high salt excretion Reduction in the risk of cardiac therapy by processing the ejection fraction.

Dosage:

The prescribing doctor adjusts the dosage according to each individual’s care. It is important to follow the prescriber’s instructions. Read the Product Insert that comes with the medication before use.

Application

Type 2 Diabetes Mellitus

• Monotherapy: when diet and exercise alone do not provide adequate blood glucose regulation in patients for whom the use of metformin is considered unsuitable due to intolerance
• Additional combination therapy: in combination with other glucose-lowering drugs including insulin, when these, along with diet and exercise, do not provide adequate blood glucose regulation

Use:

Adults

• Recommended starting dosage: 10 mg once daily.
• If tighter blood glucose regulation is needed: increase dose to 25 mg once daily
• In combination with a sulfonylurea derivative or with insulin, it may be considered to reduce the dosage of the sulfonylurea derivative or the insulin to reduce the risk of hypoglycemia

Administration method

1.  With or without food
2.  Tablets should be swallowed whole with water
3.  If a dose is missed, it should be taken as soon as the patient realizes it. No double dose should be taken on the same day.